Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-breaking Cancer Research
ESMO, the leading organisation for medical oncology, has launched an important new service for rapidly disseminating research to accelerate the transition of results into practice for the benefit of cancer patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005495/en/
“In a world that runs fast, timeliness in bringing research advances to patients is critical. The lessons that we have learnt from the COVID-19 pandemic have taught us that we need to be creative in sharing research results, and we certainly don’t have to wait for the two or three times in the year when major oncology congresses take place,” says Solange Peters, ESMO President.
ESMO Virtual Plenaries will combine concise presentations of new data, insightful discussion and audience Q&A in live, easy-to-access, 60-minute online sessions at convenient times across international time zones. They will remain available on OncologyPRO, ESMO’s online resource portal, for subsequent viewing.
Every month, latest, original scientific data will be presented from randomised phase III oncology trials or phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.
“By timely presentation of clinical and scientific data, ESMO Virtual Plenaries will be complementary to and enhance the value of conventional scientific congresses, whilst adhering to the principles of peer review, analysis and audience interaction,” says George Pentheroudakis, ESMO Chief Medical Officer.
A maximum of two abstracts will be accepted for presentation each month (except September and November when ESMO hosts major congresses). Abstracts will be original data from international investigators, selected by appropriate independent ESMO specialists. After presentation and discussion in ESMO Virtual Plenaries, abstracts will be published in Annals of Oncology and will be eligible for encore presentation at the next ESMO Congress.
The first ESMO Virtual Plenary is on Friday, 19 February, 1300 CET
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology. ESMO Members or anyone with an already existing free ESMO Account will be able to log in and watch using their existing ESMO Account.
European Society for Medical Oncology
+41 91 973 19 01
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Universal Peace Federation: Millions of participants from 150 countries joined the live online broadcast of the 5 th Rally of Hope3.3.2021 19:43:00 CET | Press release
Millions of participants from 150 countries joined the live online broadcast of the 5th Rally of Hope sponsored by the Universal Peace Federation (UPF) on Saturday, February 27, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005853/en/ Dr. Hak Ja Han Moon, Co-Founder of Universal Peace Federation delivering her message of peace to the online participants of the 5th Rally of Hope. (Photo: Business Wire) The virtual event featured world-class entertainment and globally renowned leaders including Cape Verde President Jorge Carlos Fonseca; Guyana Prime Minister Mark Phillips; U.S. Vice President Mike Pence (2017-2021); United Nations World Food Programme Executive Director David Beasley; City of Refuge Church Bishop Noel Jones; South Africa President F.W. de Klerk (1989-1994); India Vice President Mohammad Hamid Ansari (2007-2017); Oxford Vaccine co-developer Dr. Sarah Gilbert; and East Timor President Xanana Gusmão
AGCO Announces Farmer-First Strategy3.3.2021 17:50:00 CET | Press release
AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, today announced its farmer-first strategy designed to maximize value creation for its key stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005773/en/ AGCO Announces Farmer-First Strategy (Photo: Business Wire) During its 2021 Virtual Analyst Briefing, Eric Hansotia, AGCO’s Chairman, President and CEO introduced AGCO’s new Purpose and Vision statements that, when combined, offer powerful insight into the role AGCO intends to play for farmers and within the agriculture industry. AGCO’s Purpose is to deliver “Farmer-focused solutions to sustainably feed our world” and its Vision is to be the “Trusted partner for industry-leading, smart farming solutions.” AGCO will realize its Purpose and Vision by continuing to leverage its award-winning, differentiated brand portfolio to offer
Norwegian Emergency Health Services Gain Nationwide Collaboration Through Motorola Solutions’ Unified Control Room Solution3.3.2021 17:27:00 CET | Press release
Health services are a critical discipline, where every second counts and the control room is at the heart of their mission-critical operations. Teams require collaboration and flexibility to effectively manage emergency health situations as they arise. This has become especially apparent with the ongoing COVID-19 pandemic, where pressures on health services including medical communication centres, continue to rise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005158/en/ (Photo: Business Wire) Motorola Solutions announced today it has been awarded a contract by Helsetjenestens Driftsorganisasjon for Nødnett HF (HDO HF) to provide the Norwegian Health Emergency Service with a new CommandCentral Control Room Solution (CRS). “The new control room solution allows for significant improvements to efficiency and scalability, providing the much-needed flexibility between mission-critical teams”, said Lars Erik Tandsæther, CEO
H.I.G. Capital Expands European WhiteHorse Team with the Addition of Michael Lucas3.3.2021 17:08:00 CET | Press release
H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with over €35 billion of equity capital under management, is pleased to announce the expansion of its European WhiteHorse team with the addition of Michael Lucas as a Managing Director. Michael will be based in H.I.G.’s London office. Michael has 27 years of experience in leveraged finance and direct lending. Prior to joining H.I.G., he was a Founding Partner and Head of the UK at Bridgepoint Credit. Prior to that, he spent over 20 years at ING where he was most recently acting as Global Head of Financial Sponsors. Commenting on the hire, Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said, “We are thrilled to have Michael join the firm. He is one of the most respected and well-known professionals within the direct lending community in Europe, and I am confident he will have an immediate impact on our growing European direct lending platform.” About H.I.G. Capital H.I.G. is a leading global alternative asse
NZMP™ Customers Set to Benefit From New Carbonzero Certified Ingredients3.3.2021 17:00:00 CET | Press release
NZMP™, Fonterra’s dairy ingredient and solutions brand, has launched a new carbonzero certified Organic Butter. Debuting its launch in North America, the new Organic Butter will help NZMP’s customers to achieve their own sustainability goals and meet consumer demand for more sustainable products. With 72 per cent of global consumers expressing an interest in brands that actively communicate achievements around sustainability1, the introduction of carbonzero ingredients is just one way in which NZMP™ customers can leverage Fonterra’s sustainability solutions. NZMP’s™ first certified carbonzero ingredient has been audited and verified by Toitū Envirocare, an independent certifier. Lara Phillips, Senior Manager of Fonterra Sustainability Solutions, says: “Climate change is one of the most pressing challenges of our time and we’re committed to finding solutions to reduce our footprint further as part of our ongoing journey in sustainability. “To obtain carbonzero certification for an ingre
CORRECTING and REPLACING Monument Re Acquires Variable Annuity Portfolio From Athora Ireland Plc.3.3.2021 16:07:00 CET | Press release
Headline of release should read: Monument Re Acquires Variable Annuity Portfolio From Athora Ireland Plc. (instead of Monument Re Acquires Variable Annuity Portfolio From Athora Life Plc.). The updated release reads: MONUMENT RE ACQUIRES VARIABLE ANNUITY PORTFOLIO FROM ATHORA IRELAND PLC. Monument Re announced today that, subject to necessary Irish High Court and regulatory approvals, it has agreed to acquire the closed-block portfolio of variable annuities from Athora Ireland plc, a wholly-owned subsidiary of Athora Holding Ltd. Financial terms of the transaction were not disclosed. “We are pleased to have reached agreement with Athora to acquire this block of business which further reinforces our position as the market leading consolidator in Ireland,” said Manfred Maske, CEO of Monument Re. About Athora Holding Ltd. Athora is a specialised insurance and reinsurance group fully focused on the European market. Athora dedicates its focus, capital, time and technical insights to offerin
Altasciences Conducts Phase I Study in Healthy Normal Subjects for RLS-0071 for Treatment of Acute Lung Injury Due to COVID-19 Pneumonia3.3.2021 15:41:00 CET | Press release
Altasciences is pleased to support ReAlta Life Sciences by conducting a Phase I trial to evaluate RLS-0071 for treatment of Acute Lung Injury (ALI) as a result of viral infections, such as COVID-19, respiratory syncytial virus (RSV), and influenza. As part of the ReAlta ALI program underway, the Phase I trial is a single-ascending dose, randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK, and PD of RLS-0071 in healthy subjects, performed at the Altasciences clinical pharmacology unit in Montreal, Canada. Ingrid Holmes, Vice President, Global Clinical Operations at Altasciences, says, “Our teams are proud to have the opportunity to be involved in the clinical conduct and bioanalytical analysis for this important first-in-human trial. Being able to prioritize COVID-19 therapies by contributing critical data to the development of potentially life-altering medications, such as RLS-0071, is tremendously rewarding to our teams.” Click
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom